Convergence Pharmaceuticals and Selcia have entered into a drug discovery partnership to identify and develop candidate molecules to treat chronic pain.
Under the agreement, Convergence will combine its medicinal chemistry know-how, preclinical development expertise and ion-channel biology platform with Selcia’s chemistry support services and medicinal chemistry.
Dr Ged Giblin, Convergence’s head of chemistry and preclinical development, said that the combination of its platform and Selcia’s bespoke approach would provide an innovative model to finding solutions for a major unmet clinical need.
Share this article
